Sangamo BioSciences | SGMO - Interest Expense On Debt


Sangamo BioSciences reported 97.56M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Merck USD 412M 85M Dec/2025
Novartis USD 304M 23M Dec/2025
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Tectonic Therapeutic USD 12K 276.99M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025